Department of Gastroenterology, Wuhan No.1 Hospital, Wuhan, Hubei, China.
Int Wound J. 2024 Jan;21(1):e14638. doi: 10.1111/iwj.14638.
Complications related to wound healing pose substantial obstacle in the management of colorectal cancer (CRC), specifically in the field of anorectal medicine. Biosimilars of bevacizumab have emerged as crucial therapeutic agents in the management of these complications. With the particular emphasis on effects of Bevacizumab Biosimilar Plus on wound healing among patients diagnosed with CRC, this review underscores the potential of this anorectal medication to improve patient outcomes and was aimed to assess the safety and efficacy of Bevacizumab Biosimilar Plus in relation to complications associated with wound healing in patients with CRC. The assessment centers on its therapeutic potential and safety profile within the domain of anorectal medicine. In accordance with the PRISMA guidelines, a comprehensive literature search was performed, resulting in the identification of 19 pertinent studies out of an initial 918. Priority was given to assessing the safety and adverse effects of Bevacizumab Biosimilar Plus in conjunction with its effectiveness in wound healing. The extracted data comprised the following: study design, patient demographics, comprehensive treatment regimens, wound healing-specific outcomes and adverse effects. The evaluation of study quality was conducted utilizing the instruments provided by the Cochrane Collaboration and the Newcastle-Ottawa Scale (NOS). Bevacizumab Biosimilar Plus demonstrates efficacy in the management of wound healing complications among patients with CRC, with a safety and efficacy profile similar to that of the original Bevacizumab, according to the analysis. Notably, several studies reported improved rates of wound healing in relation to the biosimilar. The safety profiles exhibited similarities to the anticipated anti-VEGF agent effects. In wound management, the biosimilar also demonstrated advantages in terms of prolonged efficacy. In addition, analyses of cost-effectiveness suggested that the use of biosimilars could result in cost reductions. Bevacizumab Biosimilar Plus exhibited potential as an anorectal medication for the effective management of wound healing complications in patients with CRC. This has substantial ramifications for improving the quality of patient care, encompassing the affordability and effectiveness of treatments.
与伤口愈合相关的并发症是结直肠癌（CRC）管理中的重大障碍，特别是在肛肠医学领域。贝伐珠单抗的生物类似药已成为治疗这些并发症的重要治疗药物。鉴于贝伐珠单抗生物类似药 Plus 对诊断为 CRC 的患者伤口愈合的影响，本综述强调了这种肛肠药物改善患者预后的潜力，并旨在评估贝伐珠单抗生物类似药 Plus 与 CRC 患者伤口愈合相关并发症的安全性和疗效。评估集中在其在肛肠医学领域的治疗潜力和安全性概况。根据 PRISMA 指南，进行了全面的文献检索，从最初的 918 项研究中确定了 19 项相关研究。重点评估了贝伐珠单抗生物类似药 Plus 的安全性和不良影响及其在伤口愈合方面的有效性。提取的数据包括：研究设计、患者人口统计学、综合治疗方案、伤口愈合特定结局和不良影响。使用 Cochrane 协作组织和纽卡斯尔-渥太华量表（NOS）提供的工具对研究质量进行评估。根据分析，贝伐珠单抗生物类似药 Plus 在治疗 CRC 患者的伤口愈合并发症方面具有疗效，且安全性和疗效与原贝伐珠单抗相似。值得注意的是，几项研究报告称该生物类似药与提高的伤口愈合率有关。安全性概况与预期的抗 VEGF 药物作用相似。在伤口管理方面，该生物类似药在疗效延长方面也具有优势。此外，成本效益分析表明，使用生物类似药可能会降低成本。贝伐珠单抗生物类似药 Plus 作为一种肛肠药物，具有治疗 CRC 患者伤口愈合并发症的潜力。这对提高患者护理质量具有重大意义，包括治疗的可负担性和有效性。
